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Abstract
Background The use of ﬂuorescent proteins to label
tumors is revolutionizing cancer research, enabling imag-
ing of both primary and metastatic lesions, which is
important for diagnosis, staging, and therapy. This report
describes the use of ﬂuorescence laparoscopy to image
green ﬂuorescent protein (GFP)-expressing tumors in an
orthotopic mouse model of human pancreatic cancer.
Methods The orthotopic mouse model of human pancre-
atic cancer was established by injecting GFP-expressing
MiaPaCa-2 human pancreatic cancer cells into the pancreas
of 6-week-old female athymic mice. On postoperative day
14, diagnostic laparoscopy using both white and ﬂuores-
cent light was performed. A standard laparoscopic system
was modiﬁed by placing a 480-nm short-pass excitation
ﬁlter between the light cable and the laparoscope in addi-
tion to using a 2-mm-thick emission ﬁlter. A camera was
used that allowed variable exposure time and gain setting.
For mouse laparoscopy, a 3-mm 0 laparoscope was used.
The mouse’s abdomen was gently insufﬂated to 2 mm Hg
via a 22-gauge angiocatheter. After laparoscopy, the
animals were sacriﬁced, and the tumors were collected and
processed for histologic review. The experiments were
performed in triplicate.
Results Fluorescence laparoscopy enabled rapid imaging
of the brightly ﬂuorescent tumor in the pancreatic body.
Use of the proper ﬁlters enabled simultaneous visualization
of the tumor and the surrounding structures with minimal
autoﬂuorescence. Fluorescence laparoscopy thus allowed
exact localization of the tumor, eliminating the need to
switch back and forth between white and ﬂuorescence
lighting, under which the background usually is so dark-
ened that it is difﬁcult to maintain spatial orientation.
Conclusion The use of ﬂuorescence laparoscopy permits
the facile, real-time imaging and localization of tumors
labeled with ﬂuorescent proteins. The results described in
this report should have important clinical potential.
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Accurate staging is a crucial step in establishing the
appropriate therapeutic approach for patients with pancre-
atic cancer. Curative resection can be achieved in only 10–
20% of newly diagnosed cases [1]. Despite improvements
in computed tomography (CT), magnetic resonance imag-
ing (MRI), and endoscopic ultrasound (EUS), up to 36% of
patients deemed to have resectable disease based on pre-
operative imaging with these techniques are found at
staging laparoscopy to have unresectable disease [2, 3].
Although staging laparoscopy has been demonstrated to
improve the diagnostic yield of peritoneal and liver
metastases otherwise undetectable by preoperative imag-
ing, it is not sufﬁciently accurate [2–4]. Indeed, studies
examining the accuracy of staging laparoscopy in
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showed false-negative rates of 18–26% [5, 6]. Whereas
some authors report improved accuracy with the addition
of laparoscopic ultrasound [7], others show that false-
negative rates can remain as high as 20% [8]. Given these
problems, efforts to improve the accuracy of staging lap-
aroscopy further are necessary.
Because regular white light can be strongly absorbed
and scattered by normal surrounding tissue, metastatic foci
in the peritoneum and on the liver, which often are small
and ﬂat, can go undetected under standard examination.
The photosensitizer 5-aminolevulinic acid (ALA) and its
metabolite protoporphyrin IX (PPIX) have been used to
ﬂuorescently label a wide range of tumors including
ovarian, renal, and various gastrointestinal malignancies
for ﬂuorescence laparoscopy [9–12]. However, the reso-
lution achieved with this method needs improvement.
Our laboratory pioneered the use of ﬂuorescent proteins
for imaging tumors in mouse models [13] and has devel-
oped this technology for ﬂuorescence-guided surgery [14].
In this study, we applied ﬂuorescent protein-based imaging
to laparoscopy of human pancreatic cancer in an orthotopic
mouse model.
Our study aimed to develop ﬂuorescence laparoscopy
that strongly detects the bright signal from a ﬂuorescently
labeled tumor while still allowing adequate visualization of
the background. Such technology would be instrumental in
future clinical applications of ﬂuorescence laparoscopy,
especially for surgical navigation.
Materials and methods
Cell culture
Human MiaPaCa-2 cells were stably transduced to express
the green ﬂuorescent protein (GFP) as previously described
[15, 16]. These cells were maintained in Dulbecco’s
modiﬁed Eagle medium (DMEM) (Gibco-BRL, Grand
Island, NY, USA) supplemented with 10% fetal bovine
serum (Hyclone, Logan, UT, USA), penicillin/streptomy-
cin (Gibco-BRL), sodium pyruvate (Gibco-BRL), sodium
bicarbonate (Cellgro, Manassas, VA, USA), L-glutamine
(Gibco-BRL), and minimal essential medium (MEM)
nonessential amino acids (Gibco-BRL). Cells were incu-
bated at 37C with 5% carbon dioxide (CO2).
Animal care
Female athymic nu/nu nude mice were maintained in a
barrier facility on high-efﬁciency particulate air (HEPA)-
ﬁltered racks. The animals were fed with autoclaved lab-
oratory rodent diet (Teckland LM-485; Western Research
Products, Orange, CA, USA). All surgical procedures were
performed with the animals under anesthesia using an
intramuscular injection of 0.02 ml of a 50% ketamine, 38%
xylazine, and 12% acepromazine maleate solution. The
animals were sacriﬁced by injecting 0.05 ml of the same
solution, followed by cervical dislocation. All animal
studies were approved by the UCSD Institutional Animal
Care and Use Committee (IACUC) and conducted in
accordance with the principles and procedures outlined in
the National Institutes of Health (NIH) Guide for the Care
and Use of Animals.
Orthotopic pancreatic cancer model
MiaPaCa-2-GFP cells were harvested by trypsinization and
washed three times with serum-free medium. Viability was
veriﬁed to be greater than 95% using the Vi-Cell XR
automated cell viability analyzer (Beckman Coulter, Brea,
CA, USA). The cells were resuspended at concentrations of
1 9 10
6 per 20 ll of serum-free medium and placed on ice
before surgery.
Orthotopic implantation was performed in 6-week-old
female nude mice by ﬁrst making a 6- to 10-mm transverse
incision on the left ﬂank of the mouse through the skin and
peritoneum. The tail of the pancreas then was exposed
through this incision. Pancreatic cancer cells (1 9 10
6)
were injected into the pancreatic tail, which was subse-
quently returned into the abdomen. The incision was closed
in two layers using 6.0 Ethibond nonabsorbable suture
(Ethicon Inc., Somerville, NJ, USA).
Fluorescence laparoscopy
An ideal ﬂuorescence laparoscope should possess the fol-
lowing properties: ﬁrst, it should maximize the ﬂuores-
cence signal of the tumor to facilitate its easy and rapid
imaging. Second, it should provide a clear view of the
background and surrounding tissues to allow maintenance
of spatial orientation. This second aspect has special
importance when the scope is used in a therapeutic rather
than a strictly diagnostic capacity. To achieve these crite-
ria, we modiﬁed a standard laparoscopic system in the
following manner (Fig. 1): the excitation light source, a
300-W Xenon lamp (Stryker, Kalamazoo, MI, USA), was
ﬁltered by a 480-nm interference short-pass ﬁlter. To avoid
heat damage to the ﬁlter, this excitation ﬁlter was placed at
the end of the optical ﬁber, which delivers the light to the
laparoscope. An emission ﬁlter, whose selection is descri-
bed below, was also placed between the laparoscope and
the camera. A MultiCam 310C camera (UVP, Upland, CA,
USA), which allows variable exposure time and gain set-
ting in the controlling software (VisionWorks LS, UVP),
was used. To meet our objective of dual functionality
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and the gain was set to 97.
The emission ﬁlter was chosen from three possible
options that match in the emission band of GFP at 520 nm
(a 515-nm long-pass interference ﬁlter, a Schott OG515
glass ﬁlter, or a Schott GG495 glass ﬁlter) after the
absorption spectra of their respective combinations with the
480-nm excitation ﬁlter had been obtained. The background
transmission ratio was calculated from summing the
absorption spectra of the ﬁlter combinations and translating
the combined absorbance (A) to transmission (10
-A). The
results indicated that the 2-mm-thick Schott GG495 glass
ﬁlter was the preferred emission ﬁlter (see Results section).
This particular ﬁlter was preferable because, unlike inter-
ference ﬁlters that typically have optical density (OD) 4 (i.e.
leaking only 10
-4 of light outside the allowed spectrum) or
higher capability in blocking the background, it allows 1%
of the background to leak through. This design affords
visualization of the nonﬂuorescent tissue for navigation
while enhancing the ﬂuorescence signal of the tumor.
Mouse laparoscopy
Two weeks after orthotopic implantation of the MiaPaCa-
2-GFP cells, the mice were anesthetized before laparos-
copy. Under sterile conditions, a 22-gauge angiocatheter
was gently introduced into the abdominal cavity at an angle
to avoid injury to the underlying bowel. The catheter was
secured to the abdominal wall with a suture and connected
to the insufﬂation tubing of the laparoscopic tower. Insuf-
ﬂation was ﬁrst initiated at 1 mm Hg, then augmented to a
ﬁnal pressure of 2 mm Hg.
Next, a small incision was made higher up in the
abdomen, through which a 3-mm 0 Karl-Storz laparo-
scope (Karl-Storz GmbH & Co., Tuttlingen, Germany) was
introduced. A purse-string suture was placed around this
incision to prevent its widening and to maintain proper
insufﬂation (Fig. 2). Due to the limitations presented by the
small size of the mice, no other ports were placed. At
termination of laparoscopy, the mice were sacriﬁced for
tumor collection.
Tissue histology
At necropsy, the ﬂuorescent tumor was collected, placed in
Bouin’s solution, sectioned, and subsequently placed on
slides for histology with hematoxylin and eosin (H&E)
staining. The slides were reviewed by a pathologist to
conﬁrm the identity of the ﬂuorescent lesion.
Data processing
Images obtained during laparoscopy were not processed in
any way. Representative frames are presented. Histology
images were processed for brightness and contrast using
Photoshop Element 4 (Adobe Systems Inc., San Jose, CA,
USA).
Results
Two weeks after orthotopic implantation of MiaPaCa-2-
GFP human pancreatic cancer cells, female athymic mice
were anesthetized before undergoing a diagnostic laparos-
copy under both white and ﬂuorescence modes. By this
time, all the animals had tumors that measured approxi-
mately 1 cm in diameter. For ﬂuorescence laparoscopy,
insufﬂation to 2 mm Hg allowed ample distention of the
abdominal wall to enable adequate visualization and nav-
igation within the abdomen of the mice.
Fig. 1 Fluorescence
laparoscope for visualization
and localization of green
ﬂuorescent protein (GFP)-
labeled tumors in mice. A
laparoscopic tower was
modiﬁed to achieve a
ﬂuorescence light mode that
would permit detection of
ﬂuorescence signals while still
allowing visualization of the
background tissue. A 480-nm
short-pass ﬁlter was placed
between the light cable and the
laparoscope. A GG495 glass
ﬁlter was placed between the
laparoscope and a camera that
controls exposure time and gain.
These parameters were set to
110 ms and 97, respectively, for
the purpose of our experiment
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480-nm short-pass excitation ﬁlter was used. Three dif-
ferent emission ﬁlters were tested that all achieved excel-
lent and equivalent background suppression in the emission
band of GFP at 520 nm, which serves to create the best
contrast between ﬂuorescence and background. Addition-
ally, the distinguishing advantage of an ideal emission ﬁlter
would be preservation of sufﬁcient contrast while enough
of the background is allowed to leak through to maintain
spatial orientation.
Spectral analysis of combinations of the 480-nm exci-
tation ﬁlter with each of the three emission ﬁlters tested
demonstrated that at wavelengths shorter than 520 nm, the
GG495 ﬁlter allowed the best transmission of background
light while achieving the same degree of contrast between
ﬂuorescence and background (Fig. 3).
When either the OG515 or 515LP emission ﬁlters were
used, the ﬂuorescent tumor became visible. However, the
background became so darkened that it was impossible to
pinpoint the location of the tumor (Fig. 4a, b). To visualize
the surrounding tissue and locate the tumor, the laparo-
scope would have to be switched back and forth between
white and ﬂuorescence modes. The GG495 ﬁlter overcame
this problem (Fig. 4c). The combination of the Xenon
lamp, the 480-nm short-pass excitation ﬁlter, and the
GG495 long-pass emission ﬁlter produced a spectrum that
not only provided a sufﬁcient background but also resulted
in proper color balance. By using a camera with adjustable
exposure time and gain, these two parameters can be
optimized to compensate for the lack of intensity from the
Xenon lamp.
For the purpose of our experiment, an exposure time of
110 ms and a gain of 97 afforded clear visualization of
both the ﬂuorescent tumor and the surrounding structures.
The increasing noise due to increased gain was dynamic
and did not interfere with the diagnostic purpose. The
exposure time, however, had to be kept shorter than the
time frame of typical biologic reactions, such as the
interval of heart beats, to remain useful for navigation.
With this proper combination of instruments and light
parameters, ﬂuorescence laparoscopy permitted rapid and
easy identiﬁcation of the ﬂuorescent tumor while still
permitting visualization of the surrounding tissue. In fact,
the GFP-expressing tumor was sufﬁciently bright to enable
its instant localization (Fig. 5). Navigation through the
abdominal cavity under this ﬂuorescent mode was
straightforward because we were able to maintain an ade-
quate view of the surrounding structures.
At termination of laparoscopy, the mice were sacriﬁced,
and the identiﬁed lesions were collected for histology. The
use of H&E stain conﬁrmed that these ﬂuorescent lesions
were indeed pancreatic adenocarcinoma tumors (Fig. 6).
Discussion
Staging laparoscopy has a demonstrated role in the evalu-
ation of certain gastrointestinal malignancies, including
gastric cancer [17] and pancreatic cancer [4]. The detection
of a cancerous lesion on the surface of the peritoneum or
the liver in a minimally invasive way can spare the patient
with metastatic disease from an unnecessary and costly
celiotomy, fraught with potential complications. Unfortu-
nately, standard laparoscopy can bear false-negative rates
as high as 26%, underscoring the need to improve its
diagnostic yield [6].
Several authors have previously described the applica-
tion of ﬂuorescence technology to this endeavor, relying on
ALA-induced PPIX to highlight potentially malignant
lesions [9–12]. Although the results have been impressive,
ALA is not cancer-speciﬁc and can at times ﬂuorescently
label benign lesions [10, 11]. Labeling that is cancer-
Fig. 2 Mouse laparoscopy. To achieve laparoscopy in the mouse, a
22-gauge angiocatheter was inserted into the abdominal cavity and
attached to the insufﬂation tubing of the laparoscopic tower. The
abdomen was insufﬂated to 2 mm Hg, and a 3-mm 0 laparoscope
was introduced into the abdomen for diagnostic purposes. The
laparoscope was secured with a purse-string suture
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excitation ﬁlter and three potential emission ﬁlters. At 520 nm within
the emission band of green ﬂuorophores (green ﬂuorescent protein
[GFP], Alexa-488, ﬂuorescein), all three combinations performed
equally well. However, at shorter wavelengths, they differed signif-
icantly, resulting in different background transmission capabilities.
The 515-nm long-pass interference ﬁlter almost completely blocked
background transmission, whereas the two glass ﬁlters (GG495 and
OG515) achieved a more desirable signal-to-background ratio. The
background ratio of GG495 was appropriate for generating a non zero
background for navigation and signal detection without fully saturat-
ing the charge-coupled device (CCD) which can cause loss of detail
Fig. 4 Fluorescence signal from a green ﬂuorescent protein (GFP)-
expressing pancreatic tumor as seen with three different emission
ﬁlters. A When an interference ﬁlter was used, the ﬂuorescence signal
was strong, but the background was almost completely blocked out
and appeared nearly uniformly black. B Using the OG515 glass ﬁlter
instead, slightly more background came through, although it was still
insufﬁcient for navigation. Also, the color balance with this ﬁlter was
not optimal. C The use of the GG495 glass ﬁlter achieved a good
color balance and adequate visualization of the background while
maintaining good signal-background contrast
Fig. 5 Fluorescence laparoscopy at different angles and distances in
a mouse with orthotopically implanted green ﬂuorescent protein
(GFP)-expressing pancreatic cancer. Due to the ﬂuorescence of the
tumor, a green glow (arrow) was quickly detected at entry into
the abdominal cavity (A) which easily led to the exact localization of
the tumor within the body of the pancreas (B, C). The ﬂuorescence
signal of the tumor was easily seen. The surrounding structures,
including the bowel and its vessels remained clearly visible as well
permitting facile navigation within the abdominal cavity without the
need to ﬂip between a ﬂuorescence mode and a white light mode
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123speciﬁc and selective could be of great value. Furthermore,
the ﬂuorescence signal elicited from PPIX can be intrin-
sically weak. In one study using ALA in neurosurgery,
ﬂuorescence of the glioma evaluated was only 25% greater
than that of the normal brain tissue and was surpassed by
that of the periosteum and skin [18]. This weakness of the
ﬂuorescence signal, when translated to the laparoscopic
setting, would require a ﬂuorescence mode that inevitably
darkens the background signiﬁcantly.
Likewise, Adusumilli et al. [19] have previously
described and used GFP-guided ﬂuorescence laparoscopy
for tumor detection using a replication-competent herpes
simplex virus to label the tumors with GFP. In that study,
the investigators alternated between the use of white light
and ﬂuorescence light to spatially localize the tumor. This
could pose potential disadvantages, especially if careful
surgical navigation is required around critical structures.
As such, the value of ﬂuorescence laparoscopy is dimin-
ished when the strength of the ﬂuorescent signal is
enhanced at the expense of the visibility of the background.
With this in mind, we developed a laparoscopic ﬂuores-
cence mode that allows facile and rapid identiﬁcation and
localization of a ﬂuorescently labeled tumor while still
maintainingadequatevisualizationofthesurroundingtissue.
The clear advantage that it offers is the ability to navigate
within the abdominal cavity without losing spatial orienta-
tion, something that the standard ultraviolet light described
in previous ﬂuorescence laparoscopy reports cannot do.
Two main issues govern the efﬁcacy of ﬂuorescence
laparoscopy. First, the right ﬁlter sets must be used to
permit proper excitation of the ﬂuorescent tumor and
detection of its signal while still allowing visualization of
the surrounding tissue for navigation. Second, even with
the proper ﬁlter set in place, the exposure time of the
ﬂuorophore to the exciting light must be lengthened to
enhance the brightness of the ﬂuorescence signal, which
would otherwise be rather weak. In addition, the gain must
be adjusted to optimize visualization of both the tumor and
surrounding tissues. By modifying a standard laparoscope
with a set of excitation and emission ﬁlters that allow some
background leakage of bright light without compromising
signal-background contrast and by adjusting camera-con-
trolled parameters such as exposure time and gain, we were
able to quickly and easily detect a GFP-expressing tumor in
the body of the mouse’s pancreas.
Although we have chosen to use pancreatic cancer cells
previously engineered to highly express GFP in vivo for the
purpose of this study, it must be pointed out that a number
of methods have been used to ﬂuorescently label intrinsic,
existing tumors. Our laboratory has pioneered several of
these techniques, including the use of antibodies against
tumor antigens such as carcinoembryonic antigen (CEA) or
CA19-9 to deliver ﬂuorophores to pancreatic cancer lesions
[20, 21]. Because CEA and CA19-9 are expressed in up to
98% and 91% of pancreatic ductal adenocarcinomas,
respectively [22], the clinical application of ﬂuorophore-
conjugated antibodies directed against them should allow
identiﬁcation of almost all pancreatic adenocarcinoma
lesions. Fluorescence laparoscopy of tumors labeled with
GFP or ﬂuorescent antibodies should be a powerful tool in
the diagnosis and staging of pancreatic cancer.
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